Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
Eto M, Takagi T, Kimura G, Fukasawa S, Tamada S, Miura Y, Oya M, Sassa N, Anai S, Nozawa M, Sakai H, Perini R, Yusa W, Ikezawa H, Narita T, Tomita Y.
Eto M, et al. Among authors: yusa w.
Cancer Med. 2023 Mar;12(6):6902-6912. doi: 10.1002/cam4.5483. Epub 2022 Dec 1.
Cancer Med. 2023.
PMID: 36457273
Free PMC article.
Clinical Trial.